Geode Capital Management LLC Has $211.91 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Geode Capital Management LLC boosted its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 2.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,696,354 shares of the biotechnology company's stock after acquiring an additional 44,306 shares during the quarter. Geode Capital Management LLC owned approximately 1.78% of Sarepta Therapeutics worth $211,910,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Riggs Asset Managment Co. Inc. lifted its stake in shares of Sarepta Therapeutics by 33.3% during the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company's stock valued at $47,000 after acquiring an additional 75 shares during the period. CIBC Asset Management Inc raised its holdings in Sarepta Therapeutics by 3.3% during the 3rd quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company's stock worth $339,000 after purchasing an additional 86 shares during the last quarter. EP Wealth Advisors LLC lifted its position in Sarepta Therapeutics by 2.1% during the 2nd quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company's stock valued at $774,000 after purchasing an additional 103 shares during the period. Cambridge Investment Research Advisors Inc. boosted its stake in shares of Sarepta Therapeutics by 1.9% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company's stock valued at $1,000,000 after purchasing an additional 120 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. boosted its stake in shares of Sarepta Therapeutics by 3.4% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company's stock valued at $557,000 after purchasing an additional 145 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Sarepta Therapeutics Stock Up 2.5 %

Shares of SRPT traded up $3.08 during midday trading on Monday, hitting $126.79. The stock had a trading volume of 736,600 shares, compared to its average volume of 1,221,781. The firm has a market cap of $12.11 billion, a price-to-earnings ratio of 98.97 and a beta of 0.77. The company has a 50 day simple moving average of $123.12 and a two-hundred day simple moving average of $131.53. Sarepta Therapeutics, Inc. has a twelve month low of $89.92 and a twelve month high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on SRPT. William Blair upgraded shares of Sarepta Therapeutics to a "strong-buy" rating in a report on Friday, August 30th. Guggenheim increased their price target on Sarepta Therapeutics from $148.00 to $150.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Robert W. Baird decreased their price objective on Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating for the company in a research note on Thursday, November 7th. Royal Bank of Canada reissued an "outperform" rating and issued a $182.00 target price on shares of Sarepta Therapeutics in a research note on Monday, October 21st. Finally, StockNews.com cut Sarepta Therapeutics from a "buy" rating to a "hold" rating in a report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $178.71.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the sale, the director now directly owns 5,880 shares in the company, valued at approximately $738,234. The trade was a 21.77 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 7.70% of the stock is owned by insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.